March 2024
1. NIELSEN OH, Gubatan JM, Kolho KL, Streett SE, et al
   Updates on the management of inflammatory bowel disease from periconception to pregnancy and lactation.
   Lancet. 2024 Mar 5:S0140-6736(24)00052-7. doi: 10.1016/S0140-6736(24)00052.
   

   >> Share

   
   
2. DOLINGER M, Torres J, Vermeire S
   Crohn's disease.
   Lancet. 2024 Mar 1:S0140-6736(23)02586-2. doi: 10.1016/S0140-6736(23)02586.
   

   >> Share

   
   August 2023
3. LE BERRE C, Honap S, Peyrin-Biroulet L
   Ulcerative colitis.
   Lancet. 2023;402:571-584.
   

   >> Share

   
   March 2023
4. SANDBORN WJ, Vermeire S, Peyrin-Biroulet L, Dubinsky MC, et al
   Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies.
   Lancet. 2023 Mar 2:S0140-6736(23)00061-2. doi: 10.1016/S0140-6736(23)00061.
   

   >> Share

   
   
5. ATREYA R, Neurath MF
   The sphingosine-1-phosphate receptor agonist etrasimod in ulcerative colitis.
   Lancet. 2023 Mar 2:S0140-6736(23)00228-3. doi: 10.1016/S0140-6736(23)00228.
   

   >> Share

   
   June 2022
6. SANDS BE, Irving PM, Hoops T, Izanec JL, et al
   Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial.
   Lancet. 2022;399:2200-2211.
   

   >> Share

   
   
7. CHAPMAN TP, Satsangi J
   Head-to-head biologic therapy in Crohn's disease.
   Lancet. 2022;399:2169-2171.
   

   >> Share

   
   
8. BANARES J, Aceituno L, Jimenez A, Maynard A, et al
   Sweet's syndrome and Crohn's disease diagnosed simultaneously.
   Lancet. 2022;399:2155.
   

   >> Share

   
   May 2022
9. FERRANTE M, Panaccione R, Baert F, Bossuyt P, et al
   Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial.
   Lancet. 2022;399:2031-2046.
   

   >> Share

   
   
10. D'HAENS G, Panaccione R, Baert F, Bossuyt P, et al
    Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials.
    Lancet. 2022;399:2015-2030.
    

    >> Share

    
    
11. HIBI T
    Risankizumab for Crohn's disease.
    Lancet. 2022;399:1992-1993.
    

    >> Share

    
    
12. DANESE S, Vermeire S, Zhou W, Pangan AL, et al
    Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials.
    Lancet. 2022 May 26. pii: S0140-6736(22)00581.
    

    >> Share

    
    
13. ANANTHAKRISHNAN AN
    Upadacitinib for ulcerative colitis.
    Lancet. 2022 May 26. pii: S0140-6736(22)00778.
    

    >> Share

    
    August 2021
14. MCLORNAN DP, Pope JE, Gotlib J, Harrison CN, et al
    Current and future status of JAK inhibitors.
    Lancet. 2021;398:803-816.
    

    >> Share

    
    July 2021
15. RAMSPOTT JP, Neureiter D, Emmanuel K, Jager T, et al
    Granulomatosis with polyangiitis presents with skip lesions of the bowel.
    Lancet. 2021;398:e8.
    

    >> Share

    
    
16. SMERAT T, Khdour M, Abdoh Q, Hallak H, et al
    Assessment of health-related quality of life in patients with inflammatory bowel disease in occupied Palestinian territory: a correlation cross-sectional study.
    Lancet. 2021;398 Suppl 1:S48.
    

    >> Share

    
    June 2021
17. HOLMER AK, Singh S
    Expanding targeted immune modulators in ulcerative colitis.
    Lancet. 2021 Jun 3. pii: S0140-6736(21)00891.
    

    >> Share

    
    
18. FEAGAN BG, Danese S, Loftus EV Jr, Vermeire S, et al
    Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial.
    Lancet. 2021 Jun 3. pii: S0140-6736(21)00666.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share